Alistair Reid

5.9k total citations · 1 hit paper
70 papers, 3.6k citations indexed

About

Alistair Reid is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Alistair Reid has authored 70 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Hematology, 51 papers in Genetics and 23 papers in Rheumatology. Recurrent topics in Alistair Reid's work include Chronic Myeloid Leukemia Treatments (52 papers), Chronic Lymphocytic Leukemia Research (49 papers) and Eosinophilic Disorders and Syndromes (23 papers). Alistair Reid is often cited by papers focused on Chronic Myeloid Leukemia Treatments (52 papers), Chronic Lymphocytic Leukemia Research (49 papers) and Eosinophilic Disorders and Syndromes (23 papers). Alistair Reid collaborates with scholars based in United Kingdom, United States and Greece. Alistair Reid's co-authors include Jane F. Apperley, Dragana Milojković, John M. Goldman, David Marín, Marco Bua, Jamshid S. Khorashad, Richard Szydlo, Letizia Foroni, Hugues de Lavallade and Christos Paliompeis and has published in prestigious journals such as Journal of Clinical Oncology, Blood and NeuroImage.

In The Last Decade

Alistair Reid

69 papers receiving 3.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

2010 674 citations David Marín, Alexandra Bazeos et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alistair Reid United Kingdom	25	2.8k	2.4k	1.4k	399	389	70	3.6k
Mike Scott United Kingdom	24	3.1k 1.1×	4.4k 1.8×	1.8k 1.2×	321 0.8×	3.1k 7.9×	46	5.9k
J Gäbert France	19	2.6k 0.9×	1.0k 0.4×	404 0.3×	495 1.2×	1.3k 3.4×	38	3.9k
U Mazza Italy	21	661 0.2×	868 0.4×	132 0.1×	258 0.6×	358 0.9×	86	1.4k
Luigina Mollica Canada	15	1.0k 0.4×	665 0.3×	98 0.1×	181 0.5×	709 1.8×	53	1.9k
Elizabeth A. Morgan United States	30	535 0.2×	682 0.3×	110 0.1×	632 1.6×	788 2.0×	93	2.5k
Maria Christina Cox Italy	30	1.2k 0.4×	516 0.2×	47 0.0×	743 1.9×	850 2.2×	111	2.8k
Mark Brandt United States	28	2.0k 0.7×	850 0.4×	29 0.0×	403 1.0×	1.0k 2.7×	89	2.9k
Lucy Side United Kingdom	23	224 0.1×	103 0.0×	48 0.0×	218 0.5×	407 1.0×	50	1.8k
Jörn D. Beck Germany	22	375 0.1×	236 0.1×	106 0.1×	198 0.5×	490 1.3×	71	1.8k
Johann Hitzler Canada	27	1.2k 0.4×	389 0.2×	44 0.0×	134 0.3×	1.1k 2.8×	105	2.8k

Countries citing papers authored by Alistair Reid

Since Specialization

Citations

This map shows the geographic impact of Alistair Reid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alistair Reid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alistair Reid more than expected).

Fields of papers citing papers by Alistair Reid

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alistair Reid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alistair Reid. The network helps show where Alistair Reid may publish in the future.

Co-authorship network of co-authors of Alistair Reid

This figure shows the co-authorship network connecting the top 25 collaborators of Alistair Reid. A scholar is included among the top collaborators of Alistair Reid based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alistair Reid. Alistair Reid is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Eide, Christopher A., Luis Felipe Jave‐Suárez, Georgios Nteliopoulos, et al.. (2021). Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B. Oncogene. 40(15). 2697–2710. 26 indexed citations

Khorashad, Behzad Sorouri, Alistair Reid, Zahra Aghili, et al.. (2018). Childhood Sex-Typed Behavior and Gender Change in Individuals with 46,XY and 46,XX Disorders of Sex Development: An Iranian Multicenter Study. Archives of Sexual Behavior. 47(8). 2287–2298. 11 indexed citations

Khorashad, Behzad Sorouri, Zahra Aghili, Baudewijntje P.C. Kreukels, et al.. (2018). Mental Health and Disorders of Sex Development/Intersex Conditions in Iranian Culture: Congenital Adrenal Hyperplasia, 5-α Reductase Deficiency-Type 2, and Complete Androgen Insensitivity Syndrome. Archives of Sexual Behavior. 47(4). 931–942. 14 indexed citations

Xu, Yichen, Hua Zhang, Van T.M. Nguyen, et al.. (2015). LMTK3 Represses Tumor Suppressor-like Genes through Chromatin Remodeling in Breast Cancer. Cell Reports. 12(5). 837–849. 20 indexed citations

Naresh, Kikkeri N., Hazem Ibrahim, Stefano Lazzi, et al.. (2011). Diagnosis of Burkitt lymphoma using an algorithmic approach – applicable in both resource‐poor and resource‐rich countries. British Journal of Haematology. 154(6). 770–776. 41 indexed citations

Milojković, Dragana, Jane F. Apperley, Gareth Gerrard, et al.. (2011). Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients. Blood. 119(8). 1838–1843. 49 indexed citations

Ibrahim, Amr R., Lina Eliasson, Jane F. Apperley, et al.. (2011). Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 117(14). 3733–3736. 246 indexed citations

Marín, David, Alexandra Bazeos, François-Xavier Mahon, et al.. (2010). Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib. Journal of Clinical Oncology. 28(14). 2381–2388. 674 indexed citations breakdown →

Stokes, Paul, Alice Egerton, Ben Watson, et al.. (2010). Significant decreases in frontal and temporal [11C]-raclopride binding after THC challenge. NeuroImage. 52(4). 1521–1527. 59 indexed citations

10.

Bazeos, A., Jamshid S. Khorashad, François‐Xavier Mahon, et al.. (2009). Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients.. Blood. 114(22). 3290–3290. 15 indexed citations

11.

Milojković, Dragana, Emma Nicholson, Jane F. Apperley, et al.. (2009). Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica. 95(2). 224–231. 80 indexed citations

12.

Szydlo, Richard, et al.. (2009). Specific patterns of chromosomal gains and losses associate with t(3;14), t(8;14), and t(14;18) in diffuse large B-cell lymphoma. Cancer Genetics and Cytogenetics. 194(1). 48–52. 1 indexed citations

13.

Riches, John C., Kikkeri N. Naresh, Alistair Reid, & Donald Macdonald. (2009). Burkitt lymphoma following renal transplantation. British Journal of Haematology. 146(6). 583–583. 1 indexed citations

14.

Lavallade, Hugues de, Jane F. Apperley, Jamshid S. Khorashad, et al.. (2008). Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis. Journal of Clinical Oncology. 26(20). 3358–3363. 416 indexed citations

15.

Khorashad, Jamshid S., Hugues de Lavallade, Jane F. Apperley, et al.. (2008). Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression. Journal of Clinical Oncology. 26(29). 4806–4813. 144 indexed citations

16.

Reid, Alistair, Kay Elderfield, Ian A. Clark, et al.. (2008). Phenotype of blasts in chronic myeloid leukemia in blastic phase—Analysis of bone marrow trephine biopsies and correlation with cytogenetics. Leukemia Research. 33(3). 418–425. 14 indexed citations

17.

Khorashad, Jamshid S., Nicola Thelwell, Dragana Milojković, et al.. (2008). A new rapid and sensitive assay for detecting the T315I BCR-ABL kinase domain mutation in chronic myeloid leukaemia. Journal of Clinical Pathology. 61(7). 863–865. 8 indexed citations

18.

Lavallade, Hugues de, Jamshid S. Khorashad, Marco Bua, et al.. (2007). Long Term Durability of Major Molecular Responses for Patients Treated with Imatinib after Failure of Interferon-Alfa Is Equivalent to That of Patients Achieving Major Molecular Responses to Imatinib as Primary Therapy.. Blood. 110(11). 1037–1037. 1 indexed citations

19.

Reid, Alistair, et al.. (2006). A t(12;17)(p13;q12) identifies a distinct TEL rearrangement-negative subtype of precursor-B acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics. 165(1). 64–69. 6 indexed citations

20.

Reid, Alistair, Susan Gribble, Brian J.P. Huntly, et al.. (2001). Variant Philadelphia translocations in chronic myeloid leukaemia can mimic typical blast crisis chromosome abnormalities or classic t(9;22): a report of two cases. British Journal of Haematology. 113(2). 439–442. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact